iPSC-Derived Islet Cell Therapy Market Report – Research, Industry Analysis Reports and Market Demands

Global iPSC-Derived Islet Cell Therapy Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report

Buy now

Table of Content

1 Market Overview

2 Company Profiles

3 Market Competition, by Players

3.1 Global iPSC-Derived Islet Cell Therapy Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
- 3.2.1 Market Share of iPSC-Derived Islet Cell Therapy by Company Revenue
- 3.2.2 Top 3 iPSC-Derived Islet Cell Therapy Players Market Share in 2025
- 3.2.3 Top 6 iPSC-Derived Islet Cell Therapy Players Market Share in 2025
3.3 iPSC-Derived Islet Cell Therapy Market: Overall Company Footprint Analysis
- 3.3.1 iPSC-Derived Islet Cell Therapy Market: Region Footprint
- 3.3.2 iPSC-Derived Islet Cell Therapy Market: Company Product Type Footprint
- 3.3.3 iPSC-Derived Islet Cell Therapy Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

4.1 Global iPSC-Derived Islet Cell Therapy Consumption Value and Market Share by Type (2021-2026)
4.2 Global iPSC-Derived Islet Cell Therapy Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

5.1 Global iPSC-Derived Islet Cell Therapy Consumption Value Market Share by Application (2021-2026)
5.2 Global iPSC-Derived Islet Cell Therapy Market Forecast by Application (2027-2032)

6 North America

6.1 North America iPSC-Derived Islet Cell Therapy Consumption Value by Type (2021-2032)
6.2 North America iPSC-Derived Islet Cell Therapy Market Size by Application (2021-2032)
6.3 North America iPSC-Derived Islet Cell Therapy Market Size by Country
- 6.3.1 North America iPSC-Derived Islet Cell Therapy Consumption Value by Country (2021-2032)
- 6.3.2 United States iPSC-Derived Islet Cell Therapy Market Size and Forecast (2021-2032)
- 6.3.3 Canada iPSC-Derived Islet Cell Therapy Market Size and Forecast (2021-2032)
- 6.3.4 Mexico iPSC-Derived Islet Cell Therapy Market Size and Forecast (2021-2032)

7 Europe

7.1 Europe iPSC-Derived Islet Cell Therapy Consumption Value by Type (2021-2032)
7.2 Europe iPSC-Derived Islet Cell Therapy Consumption Value by Application (2021-2032)
7.3 Europe iPSC-Derived Islet Cell Therapy Market Size by Country
- 7.3.1 Europe iPSC-Derived Islet Cell Therapy Consumption Value by Country (2021-2032)
- 7.3.2 Germany iPSC-Derived Islet Cell Therapy Market Size and Forecast (2021-2032)
- 7.3.3 France iPSC-Derived Islet Cell Therapy Market Size and Forecast (2021-2032)
- 7.3.4 United Kingdom iPSC-Derived Islet Cell Therapy Market Size and Forecast (2021-2032)
- 7.3.5 Russia iPSC-Derived Islet Cell Therapy Market Size and Forecast (2021-2032)
- 7.3.6 Italy iPSC-Derived Islet Cell Therapy Market Size and Forecast (2021-2032)

8 Asia-Pacific

8.1 Asia-Pacific iPSC-Derived Islet Cell Therapy Consumption Value by Type (2021-2032)
8.2 Asia-Pacific iPSC-Derived Islet Cell Therapy Consumption Value by Application (2021-2032)
8.3 Asia-Pacific iPSC-Derived Islet Cell Therapy Market Size by Region
- 8.3.1 Asia-Pacific iPSC-Derived Islet Cell Therapy Consumption Value by Region (2021-2032)
- 8.3.2 China iPSC-Derived Islet Cell Therapy Market Size and Forecast (2021-2032)
- 8.3.3 Japan iPSC-Derived Islet Cell Therapy Market Size and Forecast (2021-2032)
- 8.3.4 South Korea iPSC-Derived Islet Cell Therapy Market Size and Forecast (2021-2032)
- 8.3.5 India iPSC-Derived Islet Cell Therapy Market Size and Forecast (2021-2032)
- 8.3.6 Southeast Asia iPSC-Derived Islet Cell Therapy Market Size and Forecast (2021-2032)
- 8.3.7 Australia iPSC-Derived Islet Cell Therapy Market Size and Forecast (2021-2032)

9 South America

9.1 South America iPSC-Derived Islet Cell Therapy Consumption Value by Type (2021-2032)
9.2 South America iPSC-Derived Islet Cell Therapy Consumption Value by Application (2021-2032)
9.3 South America iPSC-Derived Islet Cell Therapy Market Size by Country
- 9.3.1 South America iPSC-Derived Islet Cell Therapy Consumption Value by Country (2021-2032)
- 9.3.2 Brazil iPSC-Derived Islet Cell Therapy Market Size and Forecast (2021-2032)
- 9.3.3 Argentina iPSC-Derived Islet Cell Therapy Market Size and Forecast (2021-2032)

10 Middle East & Africa

10.1 Middle East & Africa iPSC-Derived Islet Cell Therapy Consumption Value by Type (2021-2032)
10.2 Middle East & Africa iPSC-Derived Islet Cell Therapy Consumption Value by Application (2021-2032)
10.3 Middle East & Africa iPSC-Derived Islet Cell Therapy Market Size by Country
- 10.3.1 Middle East & Africa iPSC-Derived Islet Cell Therapy Consumption Value by Country (2021-2032)
- 10.3.2 Turkey iPSC-Derived Islet Cell Therapy Market Size and Forecast (2021-2032)
- 10.3.3 Saudi Arabia iPSC-Derived Islet Cell Therapy Market Size and Forecast (2021-2032)
- 10.3.4 UAE iPSC-Derived Islet Cell Therapy Market Size and Forecast (2021-2032)

11 Market Dynamics

11.1 iPSC-Derived Islet Cell Therapy Market Drivers
11.2 iPSC-Derived Islet Cell Therapy Market Restraints
11.3 iPSC-Derived Islet Cell Therapy Trends Analysis
11.4 Porters Five Forces Analysis
- 11.4.1 Threat of New Entrants
- 11.4.2 Bargaining Power of Suppliers
- 11.4.3 Bargaining Power of Buyers
- 11.4.4 Threat of Substitutes
- 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

12.1 iPSC-Derived Islet Cell Therapy Industry Chain
12.2 iPSC-Derived Islet Cell Therapy Upstream Analysis
12.3 iPSC-Derived Islet Cell Therapy Midstream Analysis
12.4 iPSC-Derived Islet Cell Therapy Downstream Analysis

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology
14.2 Research Process and Data Source

Description

According to our (Global Info Research) latest study, the global iPSC-Derived Islet Cell Therapy market size was valued at US$ 51.45 million in 2025 and is forecast to a readjusted size of US$ 1058 million by 2032 with a CAGR of 53.7% during review period.
iPSC-Derived Islet Cell Therapy refers to regenerative medicine products in which somatic cells from autologous patients or donors are reprogrammed into induced pluripotent stem cells (iPSCs), and subsequently differentiated into islet-like cell clusters, β-cell–enriched populations, or engineered islets composed of multiple endocrine cell types. These products are designed to replace or restore impaired pancreatic islet function in patients with diabetes. They are typically developed as injectable cell suspensions, islet-like cell cluster grafts, or implantable constructs combined with immune isolation devices or bioprinted scaffolds. Key development priorities include glucose-responsive insulin secretion, cellular composition consistency, control of residual undifferentiated cells, immune rejection management, scalable GMP manufacturing, and long-term safety. The overall gross margin is approximately 60%.
Demand for this therapy is primarily driven by the long-term burden of diabetes management, the shortage of donor-derived islets, and the inability of exogenous insulin therapy to restore endogenous glucose regulation. Emerging clinical and preclinical data are gradually expanding islet replacement therapy from a small population of high-risk type 1 diabetes patients toward a broader insulin-dependent diabetes population. As a result, hospitals, research institutions, and large pharmaceutical companies are increasingly interested in standardized, scalable regenerative islet products.
Product development is focused on three main technological pathways: first, autologous iPSC-derived islet cell therapy, which emphasizes immune compatibility and personalized efficacy; second, allogeneic off-the-shelf islet cell banks, which prioritize scalable manufacturing, standardized quality release, and cost efficiency; and third, integrated approaches combining gene-edited hypoimmunogenic cells, immune isolation devices, and bioprinted scaffolds, aiming to reduce or eliminate the need for long-term immunosuppression. Procurement and partnership evaluations typically focus on cell purity, β-cell proportion, glucose-stimulated insulin secretion, release testing systems, cryostability, implant site compatibility, and long-term clinical durability.
Regionally, the United States and Europe are advancing through collaboration between large pharmaceutical companies, cell therapy developers, and device platform providers. China and Japan are also progressing rapidly, supported by strong iPSC technology foundations, active clinical research ecosystems, and favorable regenerative medicine policies. Key opportunities lie in GMP differentiation processes, master cell banks, immune protection strategies, implantable delivery systems, and companion diagnostic tools. Major risks include tumorigenicity, immune rejection, uncertain long-term efficacy, manufacturing scale-up challenges, pricing and reimbursement constraints, and regulatory approval timelines.
Report Scope
This report is a detailed and comprehensive analysis for global iPSC-Derived Islet Cell Therapy market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global iPSC-Derived Islet Cell Therapy market size and forecasts, in consumption value ($ Million), 2021-2032
Global iPSC-Derived Islet Cell Therapy market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global iPSC-Derived Islet Cell Therapy market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global iPSC-Derived Islet Cell Therapy market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for iPSC-Derived Islet Cell Therapy
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global iPSC-Derived Islet Cell Therapy market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Reprogenix Bioscience, Sana Biotechnology, Century Therapeutics, Evotec, Sernova, Aspect Biosystems, Novo Nordisk, Allele Biotechnology, SCM Lifescience, Creative Medical Technology, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
iPSC-Derived Islet Cell Therapy market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Autologous iPSC-Derived Islet Cell Therapy
HLA-Matched Allogeneic iPSC-Derived Islet Cell Therapy
Universal Allogeneic iPSC-Derived Islet Cell Therapy
Market segment by Cell Composition
Beta Cell-Enriched Clusters
Islet-Like Clusters
Endocrine Subtype-Complete Islets
Pancreatic Islet Organoids
Market segment by Immune Protection Strategy
Immunosuppression-Dependent Therapy
Encapsulation-Protected Therapy
Hypoimmune Gene-Edited Therapy
Autologous Immune-Matched Therapy
Market segment by Transplantation Site
Portal Vein or Liver Site
Subcutaneous Site
Intramuscular Site
Omental Site
Other Implantation Sites
Market segment by Application
Type 1 Diabetes
Type 2 Diabetes
Pancreatogenic Diabetes
Monogenic or Special Diabetes
Preclinical Research
Other
Market segment by players, this report covers
Reprogenix Bioscience
Sana Biotechnology
Century Therapeutics
Evotec
Sernova
Aspect Biosystems
Novo Nordisk
Allele Biotechnology
SCM Lifescience
Creative Medical Technology
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter Outline
Chapter 1, to describe iPSC-Derived Islet Cell Therapy product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of iPSC-Derived Islet Cell Therapy, with revenue, gross margin, and global market share of iPSC-Derived Islet Cell Therapy from 2021 to 2026.
Chapter 3, the iPSC-Derived Islet Cell Therapy competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and iPSC-Derived Islet Cell Therapy market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of iPSC-Derived Islet Cell Therapy.
Chapter 13, to describe iPSC-Derived Islet Cell Therapy research findings and conclusion.

Buy now